Gossamer Bio (GOSS) Return on Capital Employed (2019 - 2026)
Gossamer Bio (GOSS) posted quarterly Return on Capital Employed of 190.06% for Q1 2026, down 16813.0% year-over-year from N/an in Q1 2025, and down 41.49% quarter-over-quarter from 134.33% in Q4 2025.
Gossamer Bio (GOSS) Return on Capital Employed (2019 - 2026) Analysis & Trends
Gossamer Bio's Return on Capital Employed history runs 8 years deep, the most recent figure standing at 190.06% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 16813.0% year-over-year to 190.06%; the TTM figure through Mar 2026 stood at 190.06% (down 16813.0% YoY), while the FY2025 annual figure was 94.67%, down 7236.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 190.06%, down from 134.33% in the prior quarter.
- The five-year high for Return on Capital Employed was 20.8% in Q4 2024, with the low at 190.06% in Q1 2026.
- The 5-year median for Return on Capital Employed is 84.98% (2023), against an average of 82.02%.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed jumped 9807 bps in 2024, then tumbled 16813 bps in 2026.
- Gossamer Bio's Return on Capital Employed stood at 87.87% in 2022, then advanced by 25 bps to 66.02% in 2023, then jumped by 68 bps to 20.8% in 2024, then tumbled by 546 bps to 134.33% in 2025, then sank by 41 bps to 190.06% in 2026.
- Business Quant data shows GOSS's Return on Capital Employed at 190.06% in Q1 2026, 134.33% in Q4 2025, and 98.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | 475.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 475.91% |
| Mar 31, 2026 | -190.06% |
| Dec 31, 2025 | -134.33% |
| Sep 30, 2025 | -98.81% |
| Jun 30, 2025 | -70.29% |
| Mar 31, 2025 | -21.93% |
| Dec 31, 2024 | -20.80% |
| Sep 30, 2024 | -23.41% |
| Jun 30, 2024 | -29.27% |
| Mar 31, 2024 | -71.16% |
| Dec 31, 2023 | -66.02% |
| Sep 30, 2023 | -84.98% |
| Jun 30, 2023 | -127.34% |
| Mar 31, 2023 | -103.20% |
| Dec 31, 2022 | -87.87% |
| Sep 30, 2022 | -93.04% |
| Jun 30, 2022 | -95.43% |
| Mar 31, 2022 | -76.34% |
| Dec 31, 2021 | -66.40% |
| Sep 30, 2021 | -60.06% |